About Drug Abuse Testing
Drugs are chemical substances, which are generally used in the diagnosis, treatment, and prevention of diseases. Drugs when used as medicines have positive effects on patients; however, some people use drugs for non-medical purposes, which leads to serious health problems. Drug abuse testing is a technical analysis of biological specimen to determine the drugs or combination of drugs consumed by a person. The biological specimens used for the test are saliva, urine, blood, hair, breath, and sweat. The two main technologies used to test drug abuse are immunoassay and chromatography. Drug abuse testing is widely used in diagnostics, criminal cases, and to screen sports athletes.
TechNavio's analysts forecast the Global Drug Abuse Testing market to grow at a CAGR of 4.71 percent over the period 2013-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Drug Abuse Testing market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from sales of drug abuse testing solutions, which includes drug abuse testing kits and systems. The technologies primarily considered in the report are immunoassay and chromatography.
TechNavio's report, the Global Drug Abuse Testing Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the APAC and EMEA regions; it also covers the Global Drug Abuse Testing market landscape and its growth prospects in the coming years. The report includes a discussion on the key vendors operating in this market.
Key Regions
• Americas
• APAC
• EMEA
Key Vendors
• Bio-Rad Laboratories
• Danaher
• F. Hoffmann-La Roche
• Siemens
• Thermo Fisher Scientific
Other Prominent Vendors
• Abbott Laboratories
• Agilent Technologies
• Alere
• Biomedical Diagnostics
• Branan Medical
• OraSure Technologies
• PerkinElmer
• Psychemedics
• Quest Diagnostic
• Randox Laboratories
• Sigma-Aldrich
• Sonic Healthcare
• Waters
Market Driver
• Rise in Consumption of Illicit Drugs
• For a full, detailed list, view our report
Market Challenge
• Inability to Detect Low-dose Designer Drugs
• For a full, detailed list, view our report
Market Trend
• Increase in Number of Collaborations and M&A
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Overview
06.1 Epidemiology
06.2 Commonly Abused Drugs:
06.3 Harm Caused by Drugs Abuse
07. Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Five Forces Analysis
08. Market Segmentation by Technique
09. Geographical Segmentation
09.1 Drugs Abuse Testing Market in Americas
09.1.1 Market Size and Forecast
09.2 Drugs Abuse Testing Market in EMEA Region
09.2.1 Market Size and Forecast
09.3 Drugs Abuse Testing Market in APAC Region
09.3.1 Market Size and Forecast
10. Buying Criteria
11. Market Growth Drivers
12. Drivers and their Impact
13. Market Challenges
14. Impact of Drivers and Challenges
15. Market Trends
16. Trends and their Impact
17. Vendor Landscape
17.1 Competitive Scenario
17.1.1 Key News
17.1.2 Mergers and Acquisitions
17.2 Vendor Analysis 2013
17.3 Other Prominent Vendors
18. Key Vendor Analysis
18.1 Bio-Rad
18.1.1 Key Facts
18.1.2 Business Overview
18.1.3 Business Segmentation
18.1.4 Business Strategy
18.1.5 Business Segmentation by Revenue
18.1.6 Business Segmentation by Revenue 2011 and 2012
18.1.7 Geographical Segmentation by Revenue 2012
18.1.8 Key Developments
18.1.9 SWOT Analysis
18.2 Danaher
18.2.1 Key Facts
18.2.2 Business Overview
18.2.3 Business Segmentation
18.2.4 Revenue by Business Segmentation
18.2.5 Revenue Comparison 2012 and 2013
18.2.6 Segmentation by Geography
18.2.7 Business Strategy
18.2.8 Key Information
18.2.9 SWOT Analysis
18.3 F. Hoffmann-La Roche
18.3.1 Key Facts
18.3.2 Business Overview
18.3.3 Business Segmentation by Revenue 2013
18.3.4 Business Segmentation by Revenue 2012 and 2013
18.3.5 Geographical Segmentation by Revenue 2013
18.3.6 Business Strategy
18.3.7 Recent Developments
18.3.8 SWOT Analysis
18.4 Siemens
18.4.1 Key Facts
18.4.2 Business Overview
18.4.3 Business Segmentation 2013
18.4.4 Revenue by Business Segmentation 2013
18.4.5 Revenue Comparison by Business Segmentation 2012 and 2013
18.4.6 Geographical Segmentation by Revenue 2013
18.4.7 Business Strategy
18.4.8 Recent Developments
18.4.9 SWOT Analysis
18.5 Thermo Fisher Scientific
18.5.1 Key Facts
18.5.2 Business Overview
18.5.3 Business Segmentation
18.5.4 Business Segmentation by Revenue
18.5.5 Product Segmentation by Revenue
18.5.6 Geographical Segmentation by Revenue 2013
18.5.7 Business Strategy
18.5.8 Key Information
18.5.9 SWOT Analysis
19. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Harm Caused by Drugs Abuse
Exhibit 3: Global Drugs Abuse Testing Market 2013-2018 (US$ million)
Exhibit 4: Global Drugs Abuse Testing Market Segmentation by Technology
Exhibit 5: Global Drugs Abuse Testing Market Segmentation by Geography 2013
Exhibit 6: Drugs Abuse Testing Market in Americas 2013-2018 (US$ million)
Exhibit 7: Drugs Abuse Testing Market in EMEA Region 2013-2018 (US$ million)
Exhibit 8: Drugs Abuse Testing Market in APAC Region 2013-2018 (US$ million)
Exhibit 9: Bio-Rad: Business Segmentation
Exhibit 10: Bio-Rad: Business Segmentation by Revenue 2012
Exhibit 11: Bio-Rad: Business Segmentation by Revenue 2011 and 2012 (US$ million)
Exhibit 12: Bio-Rad: Geographical Segmentation by Revenue 2012
Exhibit 13: Danaher: Business Segmentation
Exhibit 14: Danaher: Business Segmentation 2013
Exhibit 15: Danaher: Revenue by Business Segmentation 2012 and 2013 (US$ million)
Exhibit 16: Danaher: Revenue by Geographical Segmentation 2013
Exhibit 17: F. Hoffmann-La Roche: Business Segmentation by Revenue 2013
Exhibit 18: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 19: F. Hoffmann-La Roche: Geographical Segmentation by Revenue 2013 (Pharmaceuticals)
Exhibit 20: F. Hoffmann-La Roche: Geographical Segmentation by Revenue 2013 (Diagnostics)
Exhibit 21: Siemens: Business Segmentation 2013
Exhibit 22: Siemens: Revenue by Business Segmentation 2013
Exhibit 23: Siemens: Revenue by Business Segmentation 2012 and 2013 (US$ billion)
Exhibit 24: Siemens: Geographical Segmentation by Revenue 2013
Exhibit 25: Thermo Fisher: Business Segmentation
Exhibit 26: Thermo Fisher: Business Segmentation by Revenue 2013
Exhibit 27: Thermo Fisher: Product Segmentation by Revenue 2013
Exhibit 28: Thermo Fisher: Geographical Segmentation by Revenue 2013
